Back to search

Article

Infliximab-associated Gastrointestinal Obstruction: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (2004-2024)

2025-12-08

Abstract excerpt

<h4>Background: </h4> This study aimed to analyze the reported connection between gastrointestinal obstruction and infliximab (IFX) using data from the FDA Adverse Event Reporting System (FAERS). <h4>Methods: </h4>: Using FAERS data gathered from the first quarter of 2004 (1 January 2004) to the fourth quarter of 2024 (31 December 2024), we conducted a retrospective disproportionality analysis. The standardized M...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
27fc30b1-e51d-5ee9-9d34-7f56e46e610b
DOI
10.22541/au.176519174.47477285/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Infliximab-associated Gastrointestinal Obstruction: A Pharmacovigilance Analysis of the FDA Adverse Event Reporting System (2004-2024)DOI 10.22541/au.176519174.47477285/v1
Substance-Level Disproportionate Reporting of Impaired Gastric Emptying for Five Glucagon-Like Peptide-1 Receptor Agonists: A Reproducible Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Pharmacovigilance Insights into Gastrointestinal Adverse Events of JAK Inhibitors: FAERS Signal Detection with Clinical and Pharmacological ImplicationseSemantic proximity
Adverse reactions associated with the use of ustekinumab in Crohn's disease treatment：an analysis based on the FAERS databaseSemantic proximity
Gastrointestinal adverse events associated with Riociguat: A pharmacovigilance study based on FDA adverse event reporting systemSemantic proximity
Adverse event analysis and signal detection of calcitonin gene-related peptide inhibitors using the FDA Adverse Event Reporting System databaseSemantic proximity
Class-Wide Disproportionate Reporting of Impaired Gastric Emptying Across Nine Glucagon-Like Peptide-1 Receptor Agonist Products: A Signal-Detection Analysis of the FDA Adverse Event Reporting SystemSemantic proximity
Signal Mining and Analysis of Adverse Events of Isotretinoin: 20-year real-world pharmacovigilance analysis based on the FAERS databaseSemantic proximity
Reported Drug Spectrum and Disproportionality Signals for Malignant Neoplasm Progression in FAERS: A Real-World Pharmacovigilance StudySemantic proximity
Real-world safety of zonisamide: Mining and analysis of adverse events related to zonisamide based on FAERS databaseSemantic proximity
Drug-associated acute pancreatitis in paediatric versus adult reports: a disproportionality analysis of FAERSSemantic proximity
Adverse events induced by Burosumab treatment and prediction of drug target gene: a pharmacovigilance study based on the FDA adverse event reporting system (FAERS) databaseSemantic proximity
Antibiotics and antibiotic-associated diarrhea: a real-world disproportionality study of the FDA Adverse Event Reporting System from 2004 to 2022Semantic proximity
Select a neighboring publication to make it the new centre.